Nordic Nanovector Past Earnings Performance
Past criteria checks 0/6
Nordic Nanovector's earnings have been declining at an average annual rate of -4.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 98.8% per year.
Key information
-4.6%
Earnings growth rate
12.6%
EPS growth rate
| Biotechs Industry Growth | 20.9% |
| Revenue growth rate | -98.8% |
| Return on equity | -487.5% |
| Net Margin | n/a |
| Next Earnings Update | 31 Aug 2023 |
Recent past performance updates
Recent updates
Can Nordic Nanovector (OB:NANOV) Afford To Invest In Growth?
Aug 30
Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?
Nov 09We Think Nordic Nanovector (OB:NANOV) Needs To Drive Business Growth Carefully
Jul 02Is Nordic Nanovector (OB:NANOV) In A Good Position To Invest In Growth?
Jan 06Revenue & Expenses BreakdownBeta
How Nordic Nanovector makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -311 | 79 | 0 |
| 30 Sep 22 | 0 | -388 | 78 | 0 |
| 30 Jun 22 | 0 | -434 | 85 | 0 |
| 31 Mar 22 | 0 | -445 | 86 | 0 |
| 31 Dec 21 | 0 | -441 | 84 | 0 |
| 30 Sep 21 | 0 | -418 | 77 | 0 |
| 30 Jun 21 | 0 | -402 | 74 | 0 |
| 31 Mar 21 | 0 | -425 | 73 | 0 |
| 31 Dec 20 | 0 | -417 | 70 | 0 |
| 30 Sep 20 | 0 | -444 | 81 | 0 |
| 30 Jun 20 | 0 | -450 | 85 | 0 |
| 31 Mar 20 | 0 | -436 | 84 | 0 |
| 31 Dec 19 | 0 | -434 | 87 | 0 |
| 30 Sep 19 | 0 | -384 | 81 | 0 |
| 30 Jun 19 | 0 | -366 | 77 | 0 |
| 31 Mar 19 | 0 | -339 | 77 | 0 |
| 31 Dec 18 | 0 | -338 | 70 | 0 |
| 30 Sep 18 | 0 | -335 | 75 | 0 |
| 30 Jun 18 | 0 | -345 | 76 | 0 |
| 31 Mar 18 | 0 | -329 | 73 | 0 |
| 31 Dec 17 | 0 | -294 | 75 | 0 |
| 30 Sep 17 | 0 | -267 | 74 | 0 |
| 30 Jun 17 | 0 | -243 | 69 | 0 |
| 31 Mar 17 | 0 | -227 | 62 | 0 |
| 31 Dec 16 | 0 | -236 | 57 | 0 |
| 30 Sep 16 | 0 | -207 | 52 | 0 |
| 30 Jun 16 | 0 | -207 | 51 | 0 |
| 31 Mar 16 | 0 | -203 | 50 | 0 |
| 31 Dec 15 | 0 | -173 | 48 | 0 |
| 30 Sep 15 | 0 | -169 | 44 | 0 |
| 30 Jun 15 | 0 | -118 | 32 | 0 |
| 31 Mar 15 | 0 | -86 | 25 | 0 |
| 31 Dec 14 | 0 | -64 | 17 | 0 |
| 30 Sep 14 | 0 | -45 | 10 | 0 |
| 30 Jun 14 | 0 | -38 | 8 | 0 |
| 31 Mar 14 | 0 | -26 | 6 | 0 |
| 31 Dec 13 | 0 | -17 | 4 | 0 |
| 31 Dec 12 | 0 | -13 | 4 | 0 |
Quality Earnings: NANOV is currently unprofitable.
Growing Profit Margin: NANOV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NANOV is unprofitable, and losses have increased over the past 5 years at a rate of 4.6% per year.
Accelerating Growth: Unable to compare NANOV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NANOV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: NANOV has a negative Return on Equity (-487.52%), as it is currently unprofitable.